Case 33-2011: A 56-year-old man with hypophosphatemia

New England Journal of Medicine

Volumn 365, Issue 17, 2011, Pages 1625-1635

  Bergwitz, Clemens ^a,b   Collins, Michael T ^c   Kamath, Ravi S ^a,b   Rosenberg, Andrew E ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CINACALCET; FIBROBLAST GROWTH FACTOR 23; FLUORODEOXYGLUCOSE F 18; PENTETREOTIDE IN 111; PHOSPHATE; SODIUM DIHYDROGEN PHOSPHATE; FIBROBLAST GROWTH FACTOR;

ADD ON THERAPY; ADULT; ARTICLE; BONE BIOPSY; BONE PAIN; CASE REPORT; CLINICAL EVALUATION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG WITHDRAWAL; EXCISION; FIBROSARCOMA; FOOT RADIOGRAPHY; HISTOPATHOLOGY; HUMAN; HYPOPHOSPHATEMIA; JAW RADIOGRAPHY; LABORATORY TEST; MALE; MANDIBLE TUMOR; MEDICAL HISTORY; METATARSAL BONE; MOLAR TOOTH; ONCOGENIC OSTEOMALACIA; PHYSICAL EXAMINATION; PREMOLAR TOOTH; PRIORITY JOURNAL; RECURRENT DISEASE; RIB; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRESS FRACTURE; TOOTH RADIOGRAPHY; AMELOBLAST; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; LUNG TUMOR; MANDIBLE; METABOLISM; METASTASIS; MIDDLE AGED; NEWBORN; OSTEOMALACIA; PARANEOPLASTIC SYNDROME; PATHOLOGY; TUMOR RECURRENCE;

AMELOBLASTS; DIAGNOSIS, DIFFERENTIAL; FIBROBLAST GROWTH FACTORS; FIBROSARCOMA; FRACTURES, STRESS; HUMANS; HYPOPHOSPHATEMIA; INFANT, NEWBORN; LUNG NEOPLASMS; MALE; MANDIBLE; MANDIBULAR NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OSTEOMALACIA; PARANEOPLASTIC SYNDROMES; PHOSPHATES;

EID: 80054957497     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcpc1104567     Document Type: Article

References (27)

1. Daffner RH, Pavlov H. Stress fractures: current concepts. AJR Am J Roentgenol 1992;159:245-52.
2. Stubbs J, Liu S, Quarles LD. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 2007;20:302-8.
3. Segawa H, Onitsuka A, Kuwahata M, et al. Type IIc sodium-dependent phosphate transporter regulates calcium metabolism. J Am Soc Nephrol 2009;20:104-13.
4. Bringhurst FR, Leder BZ. Regulation of calcium and phosphate homeostasis. In: DeGroot LJ, Jameson JL, eds. Endocrinology. 5th ed. Philadelphia: W.B. Saunders, 2006:805-43.
5. Bergwitz C, Jüppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 2010;61:91-104.
6. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001; 98:6500-5. (Pubitemid 32488266)
7. Kuro-o M. Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr Opin Nephrol Hypertens 2006;15:437-41. (Pubitemid 44297987)
8. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006;444:770-4. (Pubitemid 44949607)
9. Yan X, Yokote H, Jing X, et al. Fibroblast growth factor 23 reduces expression of type IIa Na+/Pi co-transporter by signaling through a receptor functionally distinct from the known FGFRs in opossum kidney cells. Genes Cells 2005;10: 489-502. (Pubitemid 40590366)
10. Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 2007; 293:F1577-F1583. (Pubitemid 350085994)
11. Razzaque MS. Klotho and Na+,K+- ATPase activity: solving the calcium metabolism dilemma? Nephrol Dial Transplant 2008;23:459-61. (Pubitemid 351767638)
12. Econs MJ, McEnery PT. Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 1997;82:674-81. (Pubitemid 27068650)
13. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;348: 1656-63. (Pubitemid 36459471)
14. Dallera P, Bertoni F, Marchetti C, Bacchini P, Campobassi A. Ameloblastic fibrosarcoma of the jaw: report of five cases. J Craniomaxillofac Surg 1994;22:349-54.
15. Muller S, Parker DC, Kapadia SB, Budnick SD, Barnes EL. Ameloblastic fibrosarcoma of the jaws: a clinicopathologic and DNA analysis of five cases and review of the literature with discussion of its relationship to ameloblastic fibroma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;79:469-77.
16. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia- associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 2004;28:1-30. (Pubitemid 38031617)
17. Jefferis AF, Taylor PC, Walsh-Waring GP. Tumour-associated hypophosphataemic osteomalacia occurring in a patient with an odontogenic tumour of the maxilla. J Laryngol Otol 1985;99:1011-7. (Pubitemid 16227434)
18. Roarke MC, Nguyen BD. PET/CT localization of phosphaturic mesenchymal neoplasm causing tumor-induced osteomalacia. Clin Nucl Med 2007;32:300-1. (Pubitemid 46569318)
19. Jan de Beur SM, Streeten EA, Civelek AC, et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 2002;359:761-3. (Pubitemid 34215078)
20. Hesse E, Moessinger E, Rosenthal H, et al. Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography. J Bone Miner Res 2007;22:158-62. (Pubitemid 46032609)
21. Takeuchi Y, Suzuki H, Ogura S, et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 2004;89:3979-82. (Pubitemid 39071502)
22. Andreopoulou P, Dumitrescu CE, Kelly MH, et al. Selective venous catheterization for the localization of phosphaturic mesenchymal tumors. J Bone Miner Res 2011;26:1295-302.
23. Hesse E, Rosenthal H, Bastian L. Radiofrequency ablation of a tumor causing oncogenic osteomalacia. N Engl J Med 2007;357:422-4. (Pubitemid 47124162)
24. Geller JL, Khosravi A, Kelly MH, Riminucci M, Adams JS, Collins MT. Cinacalcet in the management of tumorinduced osteomalacia. J Bone Miner Res 2007;22:931-7.
25. Gupta A, Winer K, Econs MJ, Marx SJ, Collins MT. FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab 2004;89:4489-92. (Pubitemid 39244460)
26. Harvey JN, Gray C, Belchetz PE. Oncogenous osteomalacia and malignancy. Clin Endocrinol (Oxf) 1992;37:379-82.
27. Aono Y, Yamazaki Y, Yasutake J, et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res 2009;24: 1879-88.